COVID-19 Funding Opportunities

I. Biomedical Advanced Research and Development Authority (BARDA)
BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat. BARDA, with a total budget of $512 Million, is seeking proposals through the following mechanisms:

**View Solicitation**
**Topic:** Products to diagnose, prevent or treat novel coronavirus infections
**Due Date:** Rolling, through 10/31/2020
**Budget:** Unlimited

**Division of Research, Innovation & Ventures (DRIVe) BAA**
**View Solicitation**
**Topics:** Diagnostic assays, screening and model development, vaccines, advanced manufacturing.
**Due Date:** Abstract submissions due by 5PM ET on 6/30/2020.
**Budget:** $750,000

II. Centers for Disease Control and Prevention (CDC)
The Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) have released several funding opportunities focused on COVID-19.

**CDC: Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nations Health**
**View Solicitation**
**Topic:** Building capacity in the following emergency/crisis response areas: Incident Management for Early Crisis Response, Jurisdictional Recovery, Biosurveillance, Information Management, Mitigation, Surge Management, Communications.
**Due Date:** 4/2/2020
**Budget:** $300,000 – $3,000,000

III. National Institutes of Health (NIH)
**Notices of Special Interest (NOSI)**
Multiple NIH Institutes have issued a Notice of Special Interest (NOSI) to provide funding for Administrative Supplements on research topics related to COVID-19. To be eligible for these Supplements, the applicant must have an active award through the Institute with sufficient time remaining to complete all studies proposed.

**National Heart, Lung, Blood Institute (NHLBI)**
**Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)**
**View Solicitation**
**Topic:** NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.
**Due Date:** Rolling, through 10/5/2020
**Budget:** Not specified
**National Institute of Allergy and Infectious Diseases (NIAID)**
**National Institute of General Medical Sciences (NIGMS)**
Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

*View Solicitation*

**Topic:** NIAID is particularly interested in projects focusing on viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against 2019-nCoV. NIGMS is specifically interested in incorporation of data from the 2019-nCoV into ongoing research efforts to develop predictive models for the spread of Coronavirus and related pathogens.

**Due Date:** Rolling, through 2/21/2021

**Budget:** Not specified

**National Institute of Drug Abuse (NIDA)**
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

*View Solicitation*

**Topic:** NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

**Due Date:** Rolling, through 3/31/2021

**Budget:** Maximum of $100,000 direct costs per year for 2 years. Higher budgets may be considered with justification.

**IV. National Science Foundation (NSF)**

**Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19**

NSF is seeking Phase I SBIR/STTR proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis.

*View Letter*

**Topics:** Artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations.

**Due Date:** Rolling, Project Pitch submission required

**Budget:** $225,000

**Dear Colleague Letter on the Coronavirus**

*View Letter*

The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge. For proposals of up to $200K, NSF encourages using the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency.


*View Letter*

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.
V. Other US Funding Agencies

Medical Technology Enterprise Consortium (MTEC)

MTEC-20-09-COVID-19_Treatment_MIDRP “Development of Treatments for COVID-19”

MTEC is an enterprise partnership in collaboration with industry and academia to facilitate research and development activities, in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) and other DoD agencies in the biomedical sciences MTEC membership is not required for proposal submission, but it is required for an award.

View Solicitation

Topics: Therapeutic(s) that can treat COVID-19. Treatments with potential application to the prevention of COVID-19 infection are desired. Therapeutics that can be administered in a non-hospital environment are desired.

Enhanced White Paper Due Date: 4/8/2020

Budget: Up to $5,000,000

Coalition for Epidemic Preparedness Innovation (CEPI)

Multi-purpose platform technologies for rapid response against emerging infectious diseases

View Solicitations

Topic: Vaccine and adaptive epidemic response platform development

Due Date: Expressions of Interest (EOIs) will be accepted on a rolling basis until 10/14/2020.

Budget: Not specified

Medical CBRN Defense Consortium (MCDC)

Request for Information (RFI) – CoV Pandemic Response

View Solicitation

MCDC is requesting proposals regarding rapidly deployable (1-6 months) products and technologies to combat the current pandemic. Longer-term solutions are not requested in this RFI.

Topic: COVID-19-related Diagnostics/Monitoring, Surveillance, Information Systems for Point of Care, Therapeutics, Prophylactics, Clinical Trials

Due Date: 5/31/2020

Budget: Not Specified